Table 1.
Patient characteristics
| Characteristics | No (%) |
|---|---|
| Demographic characteristics | |
| Total patients | 18 |
| Grade 4 glioblastoma | 18 (100%) |
| Age, y | 55 (range 48-70) |
| Sex | |
| Male | 10 (56%) |
| Female | 8 (44%) |
| Evidence for enhancing tumor on preoperative ceMRI | 18 (100%) |
| MET-PET scans | |
| Scan 1: Postoperative | 18 (100%) |
| Scan 2: Postchemoradiation | 14 (78%) |
| Tumor characteristics | |
| MGMT hypermethylation status | |
| Methylated | 8 (44%) |
| Not methylated | 8 (44%) |
| Unknown | 2 (12%) |
| EGFR amplification | |
| Positive | 5 (28%) |
| Negative | 11 (61%) |
| Unknown | 2 (12%) |
| MET amplification | |
| Positive | 2 (12%) |
| Negative | 14 (78%) |
| Unknown | 2 (12%) |
| IDH-1 gene mutation status | |
| Wildtype | 18 (100%) |
| Mutated | 0 (0%) |
Abbreviations: ceMRI = contrast-enhanced magnetic resonance imaging; EGFR = epidermal growth factor receptor; IDH-1 = isocitrate dehydrogenase 1; MET = methionine; MGMT = O6-methylguanine-DNA methyltransferase; PET = positron emission tomography.